» Articles » PMID: 38638122

Stigma Associated with Genetic Testing for Rare Diseases-causes and Recommendations

Overview
Journal Front Genet
Date 2024 Apr 19
PMID 38638122
Authors
Affiliations
Soon will be listed here.
Abstract

Rare disease (RD) is a term used to describe numerous, heterogeneous diseases that are geographically disparate. Approximately 400 million people worldwide live with an RD equating to roughly 1 in 10 people, with 71.9% of RDs having a genetic origin. RDs present a distinctive set of challenges to people living with rare diseases (PLWRDs), their families, healthcare professionals (HCPs), healthcare system, and societies at large. The possibility of inheriting a genetic disease has a substantial social and psychological impact on affected families. In addition to other concerns, PLWRDs and their families may feel stigmatized, experience guilt, feel blamed, and stress about passing the disease to future generations. Stigma can affect all stages of the journey of PLWRDs and their families, from pre-diagnosis to treatment access, care and support, and compliance. It adversely impacts the quality of life of RD patients. To better explore the impact of stigma associated with genetic testing for RDs, we conducted a literature search on PubMed and Embase databases to identify articles published on stigma and RDs from January 2013 to February 2023. There is a dearth of literature investigating the dynamics of stigma and RD genetic testing. The authors observed that the research into the implications of stigma for patient outcomes in low- and middle-income countries (LMICs) and potential interventions is limited. Herein, the authors present a review of published literature on stigma with a focus on RD genetic testing, the associated challenges, and possible ways to address these.

Citing Articles

Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon.

Delgado-Vega A, Cederroth H, Taylan F, Ekholm K, Ek M, Thonberg H Nat Genet. 2024; 56(11):2287-2294.

PMID: 39433890 DOI: 10.1038/s41588-024-01941-1.


Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials.

Baynam G, Baker S, Steward C, Summar M, Halley M, Pariser A Pharmaceut Med. 2024; 38(4):261-276.

PMID: 38977611 PMC: 11781258. DOI: 10.1007/s40290-024-00529-8.

References
1.
Tsai G, Cameron C, Czerwinski J, Mendez-Figueroa H, Peterson S, Noblin S . Attitudes Towards Prenatal Genetic Counseling, Prenatal Genetic Testing, and Termination of Pregnancy among Southeast and East Asian Women in the United States. J Genet Couns. 2017; 26(5):1041-1058. DOI: 10.1007/s10897-017-0084-9. View

2.
Chediak L, Bedlington N, Gadson A, Kent A, Khalek A, Rosen L . Unlocking sociocultural and community factors for the global adoption of genomic medicine. Orphanet J Rare Dis. 2022; 17(1):191. PMC: 9097338. DOI: 10.1186/s13023-022-02328-3. View

3.
Boycott K, Ardigo D . Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat Rev Drug Discov. 2017; 17(3):151-152. DOI: 10.1038/nrd.2017.246. View

4.
Tan R, Kaur N, Kumar P, Tay E, Leong A, Chen M . Clinics as spaces of costly disclosure: HIV/STI testing and anticipated stigma among gay, bisexual and queer men. Cult Health Sex. 2019; 22(3):307-320. DOI: 10.1080/13691058.2019.1596313. View

5.
Ferreira C . The burden of rare diseases. Am J Med Genet A. 2019; 179(6):885-892. DOI: 10.1002/ajmg.a.61124. View